CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity.

CD1d deletion or targeting reduces breast tumor growth and improves anti-PD-1 therapy by remodeling tumor-infiltrating myeloid cells, increasing inflammatory monocytes.

• Why it matters: Understanding how myeloid cells influence tumor progression and immunotherapy response is critical for developing more effective treatments, as their diverse functions are not fully understood.
• What they did: Researchers used mouse models of breast cancer to genetically delete or target CD1d, analyzing effects on tumor growth, immune infiltration, and myeloid cell programs through single-cell RNA sequencing.
• The result: Targeting CD1d enhanced proinflammatory myeloid responses, correlated with better clinical outcomes and immunotherapy efficacy, suggesting CD1d as a promising therapeutic target to modulate tumor immunity.